{
    "abstract": "Background: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged \u226550 years. Methods: In this open label, multi-center study (NCT02045836), participants were randomized 1:1 to receive either the first dose of RZV and PPSV23, co-administered at Day 0 and the second dose of RZV at Month 2 (Co-Ad group), or PPSV23 at Day 0, the first dose of RZV at Month 2 and second dose of RZV at Month 4 (Control group). Co-primary objectives were the RZV vaccine response rate (VRR) in the Co-Ad group and the non-inferiority of the antibody responses to RZV and PPSV23 in the Co-Ad group compared to the Control group. Reactogenicity and safety were also assessed. Results: 865 participants were vaccinated (Co-Ad: 432, Control: 433). VRRs to RZV were >98% in both groups. Humoral immune responses to co-administration of RZV and PPSV23 were non-inferior to sequential administration. All three co-primary immunogenicity objectives were met. Solicited local symptoms after the first RZV dose were reported by similar percentages of participants in both groups. Solicited general symptoms were more frequently reported when the first dose of RZV and PPSV23 were co-administered. No differences were apparent between groups after the second RZV dose. Conclusions: No immunologic interference was observed between RZV and PPSV23 when co-administered in adults \u226550 years. No safety concerns were raised.",
    "author_highlights": [
        {
            "endOffset": 16374,
            "sentence": "Reactivation of latent varicella-zoster virus causes herpes zoster (HZ).",
            "startOffset": 16302
        },
        {
            "endOffset": 16479,
            "sentence": "The adjuvanted recombinant zoster vaccine (RZV) is >90% efficacious against HZ in adults aged \u226550 years.",
            "startOffset": 16375
        },
        {
            "endOffset": 16586,
            "sentence": "Immunogenicity and safety of RZV and PPSV23 were assessed when administered concomitantly or sequentially.",
            "startOffset": 16480
        },
        {
            "endOffset": 16672,
            "sentence": "No immunologic interference was observed between RZV and PPSV23 when co-administered.",
            "startOffset": 16587
        },
        {
            "endOffset": 16725,
            "sentence": "No safety concerns were identified during the study.",
            "startOffset": 16673
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Dworkin"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Breuer"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Backonja"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Maija L.",
                    "initial": "M.L.",
                    "last": "Haanp\u00e4\u00e4"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "McKendrick"
                },
                {
                    "first": "Turo J.",
                    "initial": "T.J.",
                    "last": "Nurmikko"
                },
                {
                    "first": "Anne Louise",
                    "initial": "A.L.",
                    "last": "Oaklander"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Pavan-Langston"
                },
                {
                    "first": "Karin L.",
                    "initial": "K.L.",
                    "last": "Petersen"
                },
                {
                    "first": "Michael C.",
                    "initial": "M.C.",
                    "last": "Rowbotham"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Brett R.",
                    "initial": "B.R.",
                    "last": "Stacey"
                },
                {
                    "first": "Stephen K.",
                    "initial": "S.K.",
                    "last": "Tyring"
                },
                {
                    "first": "Albert J.M.",
                    "initial": "A.J.M.",
                    "last": "Van Wijck"
                },
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Wallace"
                },
                {
                    "first": "Sawko W.",
                    "initial": "S.W.",
                    "last": "Wassilew"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Whitley"
                }
            ],
            "doi": "10.1086/510206",
            "firstpage": "S1",
            "issn": "10584838",
            "lastpage": "S26",
            "pmid": "17143845",
            "pub_year": 2007,
            "title": "Recommendations for the management of herpes zoster",
            "volume": "44"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Jeffrey I.",
                    "initial": "J.I.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMcp1302674",
            "firstpage": "255",
            "issn": "00284793",
            "lastpage": "263",
            "pmid": "23863052",
            "pub_year": 2013,
            "title": "Herpes Zoster",
            "volume": "369"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Ralph P.",
                    "initial": "R.P.",
                    "last": "Insinga"
                },
                {
                    "first": "Robbin F.",
                    "initial": "R.F.",
                    "last": "Itzler"
                },
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Pellissier"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                },
                {
                    "first": "Alexander A.",
                    "initial": "A.A.",
                    "last": "Nikas"
                }
            ],
            "doi": "10.1111/j.1525-1497.2005.0150.x",
            "firstpage": "748",
            "issn": "08848734",
            "lastpage": "753",
            "pmid": "16050886",
            "pub_year": 2005,
            "title": "The incidence of herpes zoster in a United States administrative database",
            "volume": "20"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Wollan"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "St. Sauver"
                },
                {
                    "first": "Marge J.",
                    "initial": "M.J.",
                    "last": "Kurland"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                }
            ],
            "doi": "10.4065/82.11.1341",
            "firstpage": "1341",
            "issn": "00256196",
            "lastpage": "1349",
            "pub_year": 2007,
            "title": "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction",
            "volume": "82"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Gershon"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Breuer"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Anne Louise",
                    "initial": "A.L.",
                    "last": "Oaklander"
                },
                {
                    "first": "Paul D.",
                    "initial": "P.D.",
                    "last": "Griffiths"
                }
            ],
            "doi": "10.1016/S1386-6532(10)70002-0",
            "firstpage": "S2",
            "issn": "13866532",
            "lastpage": "S7",
            "pmid": "20510263",
            "pub_year": 2010,
            "title": "Advances in the understanding of the pathogenesis and epidemiology of herpes zoster",
            "volume": "48"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Jane F.",
                    "initial": "J.F.",
                    "last": "Seward"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "CE2",
            "pmid": "18528318",
            "pub_year": 2008,
            "title": "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).",
            "volume": "57"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Jane H.",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Gary R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Anthony R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Caulfield"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Clair"
                },
                {
                    "first": "Jeffrey G.",
                    "initial": "J.G.",
                    "last": "Smith"
                },
                {
                    "first": "Harold",
                    "initial": "H.",
                    "last": "Stanley"
                },
                {
                    "first": "Rocio D.",
                    "initial": "R.D.",
                    "last": "Marchese"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "Heather M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Sch\u00f6del"
                },
                {
                    "first": "Vicki A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "Carol A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "Steve E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Larry E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                }
            ],
            "doi": "10.1086/605611",
            "firstpage": "1068",
            "issn": "00221899",
            "lastpage": "1077",
            "pmid": "19712037",
            "pub_year": 2009,
            "title": "Varicella-zoster vrrus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine",
            "volume": "200"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                }
            ],
            "firstpage": "S13",
            "issn": "00986151",
            "lastpage": "S17",
            "pmid": "19553630",
            "pub_year": 2009,
            "title": "Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence",
            "volume": "109"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Barbara H.",
                    "initial": "B.H.",
                    "last": "Johnson"
                },
                {
                    "first": "Liisa",
                    "initial": "L.",
                    "last": "Palmer"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Gatwood"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Lenhart"
                },
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1186/s12879-015-1262-8",
            "issn": "14712334",
            "pmid": "26546419",
            "pub_year": 2015,
            "title": "Annual incidence rates of herpes zoster among an immunocompetent population in the United States",
            "volume": "15"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Keay"
                },
                {
                    "first": "Jon E.",
                    "initial": "J.E.",
                    "last": "Stek"
                },
                {
                    "first": "Nickoya D.",
                    "initial": "N.D.",
                    "last": "Bundick"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Yanli",
                    "initial": "Y.",
                    "last": "Zhao"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Paula W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                }
            ],
            "doi": "10.1093/cid/cir970",
            "firstpage": "922",
            "issn": "10584838",
            "lastpage": "928",
            "pmid": "22291101",
            "pub_year": 2012,
            "title": "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years",
            "volume": "54"
        },
        "b0060": {
            "authors": [
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Boardman"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "J. Hongyuan",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "P. N.",
                    "initial": "P.N.",
                    "last": "Peduzzi"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Beisel"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Keller"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Kyriakides"
                },
                {
                    "first": "C. Y.",
                    "initial": "C.Y.",
                    "last": "Chan"
                },
                {
                    "first": "I. S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "W. W.B.",
                    "initial": "W.W.B.",
                    "last": "Wang"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Silber"
                }
            ],
            "doi": "10.1056/NEJMoa051016",
            "firstpage": "2271",
            "issn": "00284793",
            "lastpage": "2365",
            "pmid": "15930418",
            "pub_year": 2005,
            "title": "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "352"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Craig M.",
                    "initial": "C.M.",
                    "last": "Hales"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael",
                    "initial": "I.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Stephanie R.",
                    "initial": "S.R.",
                    "last": "Bialek"
                }
            ],
            "firstpage": "729",
            "issn": "01492195",
            "lastpage": "731",
            "pmid": "25144544",
            "pub_year": 2014,
            "title": "Update on recommendations for use of herpes zoster vaccine",
            "volume": "63"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0080": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0085": null,
        "b0090": null,
        "b0095": null,
        "b0100": null,
        "b0105": {
            "authors": [
                {
                    "first": "Paul V.",
                    "initial": "P.V.",
                    "last": "Targonski"
                },
                {
                    "first": "Gregory A.",
                    "initial": "G.A.",
                    "last": "Poland"
                }
            ],
            "firstpage": "401",
            "issn": "08911150",
            "lastpage": "414",
            "pmid": "17569198",
            "pub_year": 2007,
            "title": "Pneumococcal vaccination in adults: Recommendations, trends, and prospects",
            "volume": "74"
        },
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Shu Ling",
                    "initial": "S.L.",
                    "last": "Hoshi"
                },
                {
                    "first": "Masahide",
                    "initial": "M.",
                    "last": "Kondo"
                },
                {
                    "first": "Ichiro",
                    "initial": "I.",
                    "last": "Okubo"
                }
            ],
            "doi": "10.1371/journal.pone.0139140",
            "issn": "19326203",
            "pmid": "26444287",
            "pub_year": 2015,
            "title": "Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan",
            "volume": "10"
        },
        "b0120": {
            "authors": [
                {
                    "first": "David S.",
                    "initial": "D.S.",
                    "last": "Fedson"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Nicolas-Spony"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Klemets"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Van Der Linden"
                },
                {
                    "first": "Agostinho",
                    "initial": "A.",
                    "last": "Marques"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Salleras"
                },
                {
                    "first": "Sandrine I.",
                    "initial": "S.I.",
                    "last": "Samson"
                }
            ],
            "doi": "10.1586/erv.11.99",
            "firstpage": "1143",
            "issn": "14760584",
            "lastpage": "1167",
            "pmid": "21810065",
            "pub_year": 2011,
            "title": "Pneumococcal polysaccharide vaccination for adults: New perspectives for Europe",
            "volume": "10"
        },
        "b0125": null,
        "b0130": null,
        "b0135": {
            "authors": [
                {
                    "first": "Walter W.",
                    "initial": "W.W.",
                    "last": "Williams"
                },
                {
                    "first": "Peng Jun",
                    "initial": "P.J.",
                    "last": "Lu"
                },
                {
                    "first": "Alissa",
                    "initial": "A.",
                    "last": "O'Halloran"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Kim"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Grohskopf"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Tami H.",
                    "initial": "T.H.",
                    "last": "Skoff"
                },
                {
                    "first": "Noele P.",
                    "initial": "N.P.",
                    "last": "Nelson"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Lauri E.",
                    "initial": "L.E.",
                    "last": "Markowitz"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Rodriguez-Lainz"
                },
                {
                    "first": "Amy Parker",
                    "initial": "A.P.",
                    "last": "Fiebelkorn"
                }
            ],
            "doi": "10.15585/mmwr.ss6611a1",
            "firstpage": "1",
            "issn": "15460738",
            "lastpage": "28",
            "pmid": "28472027",
            "pub_year": 2017,
            "title": "Surveillance of vaccination coverage among adult populations-United States, 2015",
            "volume": "66"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Libutti"
                },
                {
                    "first": "Lorna B.",
                    "initial": "L.B.",
                    "last": "Pais"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Dykes"
                },
                {
                    "first": "Porter",
                    "initial": "P.",
                    "last": "Anderson"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Whitin"
                },
                {
                    "first": "Harry L.",
                    "initial": "H.L.",
                    "last": "Keyserling"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                }
            ],
            "firstpage": "415",
            "issn": "1071412X",
            "lastpage": "422",
            "pmid": "9220157",
            "pub_year": 1997,
            "title": "Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells",
            "volume": "4"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Burton"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                }
            ],
            "doi": "10.1128/CVI.00112-06",
            "firstpage": "1004",
            "issn": "15566811",
            "lastpage": "1009",
            "pmid": "16960111",
            "pub_year": 2006,
            "title": "Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies",
            "volume": "13"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J. Anneke R.",
                    "initial": "J.A.R.",
                    "last": "Van den Hoek"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.019",
            "firstpage": "1745",
            "issn": "0264410X",
            "lastpage": "1753",
            "pmid": "24508036",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study",
            "volume": "32"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Andrews"
                },
                {
                    "first": "Won Suk",
                    "initial": "W.S.",
                    "last": "Choi"
                },
                {
                    "first": "Meral",
                    "initial": "M.",
                    "last": "Esen"
                },
                {
                    "first": "Hideyuki",
                    "initial": "H.",
                    "last": "Ikematsu"
                },
                {
                    "first": "Martina Kovac",
                    "initial": "M.K.",
                    "last": "Choma"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "St\u00e9phanie",
                    "initial": "S.",
                    "last": "Ravault"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Salaun"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Carline Vanden",
                    "initial": "C.V.",
                    "last": "Abeele"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Van den Steen"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Vastiau"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/infdis/jiy095",
            "firstpage": "1750",
            "issn": "00221899",
            "lastpage": "1760",
            "pmid": "29529222",
            "pub_year": 2018,
            "title": "Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older",
            "volume": "217"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "Gini",
                    "initial": "G.",
                    "last": "van Rijckevorsel"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Gr\u00e9gory",
                    "initial": "G.",
                    "last": "Catteau"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.09.073",
            "firstpage": "863",
            "issn": "0264410X",
            "lastpage": "868",
            "pmid": "26432913",
            "pub_year": 2016,
            "title": "Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults",
            "volume": "34"
        },
        "b0165": {
            "authors": [
                {
                    "first": "C. Raina",
                    "initial": "C.R.",
                    "last": "MacIntyre"
                },
                {
                    "first": "Tony",
                    "initial": "T.",
                    "last": "Egerton"
                },
                {
                    "first": "Malcolm",
                    "initial": "M.",
                    "last": "McCaughey"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                },
                {
                    "first": "Bernadette V.",
                    "initial": "B.V.",
                    "last": "Campbell"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Marco F.",
                    "initial": "M.F.",
                    "last": "Pagnoni"
                },
                {
                    "first": "Jon E.",
                    "initial": "J.E.",
                    "last": "Stek"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Xu"
                },
                {
                    "first": "Paula W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Jeffrey L.",
                    "initial": "J.L.",
                    "last": "Silber"
                }
            ],
            "doi": "10.4161/hv.6.11.12852",
            "firstpage": "894",
            "issn": "15548600",
            "lastpage": "902",
            "pmid": "20980796",
            "pub_year": 2010,
            "title": "Concomitant administration of zoster and pneumococcal vaccines in adults \u226560 years old",
            "volume": "6"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Hung Fu",
                    "initial": "H.F.",
                    "last": "Tseng"
                },
                {
                    "first": "Ning",
                    "initial": "N.",
                    "last": "Smith"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Jacobsen"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.018",
            "firstpage": "3628",
            "issn": "0264410X",
            "lastpage": "3632",
            "pmid": "21435407",
            "pub_year": 2011,
            "title": "Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine",
            "volume": "29"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Marcia J.",
                    "initial": "M.J.",
                    "last": "Wyman"
                },
                {
                    "first": "Katie L.",
                    "initial": "K.L.",
                    "last": "Stabi"
                }
            ],
            "doi": "10.1345/aph.1R742",
            "firstpage": "1064",
            "issn": "10600280",
            "lastpage": "1068",
            "pmid": "23715069",
            "pub_year": 2013,
            "title": "Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage",
            "volume": "47"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Naresh",
                    "initial": "N.",
                    "last": "Aggarwal"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Moeckesch"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Schenkenberger"
                },
                {
                    "first": "Carine",
                    "initial": "C.",
                    "last": "Claeys"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Douha"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Katrijn",
                    "initial": "K.",
                    "last": "Grupping"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Marta Lopez",
                    "initial": "M.L.",
                    "last": "Fauqued"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Van Den Steen"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                }
            ],
            "doi": "10.1093/infdis/jix481",
            "firstpage": "1352",
            "issn": "00221899",
            "lastpage": "1361",
            "pmid": "29029224",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older",
            "volume": "216"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Joon Young",
                    "initial": "J.Y.",
                    "last": "Song"
                },
                {
                    "first": "Hee Jin",
                    "initial": "H.J.",
                    "last": "Cheong"
                },
                {
                    "first": "T. F.",
                    "initial": "T.F.",
                    "last": "Tsai"
                },
                {
                    "first": "Hyun ah",
                    "initial": "H.a.",
                    "last": "Chang"
                },
                {
                    "first": "Min Joo",
                    "initial": "M.J.",
                    "last": "Choi"
                },
                {
                    "first": "Ji Ho",
                    "initial": "J.H.",
                    "last": "Jeon"
                },
                {
                    "first": "Seong Hee",
                    "initial": "S.H.",
                    "last": "Kang"
                },
                {
                    "first": "Eun Ju",
                    "initial": "E.J.",
                    "last": "Jeong"
                },
                {
                    "first": "Ji Yun",
                    "initial": "J.Y.",
                    "last": "Noh"
                },
                {
                    "first": "Woo Joo",
                    "initial": "W.J.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.05.003",
            "firstpage": "4647",
            "issn": "0264410X",
            "lastpage": "4652",
            "pmid": "25980426",
            "pub_year": 2015,
            "title": "Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults",
            "volume": "33"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Alejandra",
                    "initial": "A.",
                    "last": "Gurtman"
                },
                {
                    "first": "Kathryn",
                    "initial": "K.",
                    "last": "Rice"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Richard N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Jones"
                },
                {
                    "first": "Daniel A.",
                    "initial": "D.A.",
                    "last": "Scott"
                },
                {
                    "first": "Emilio A.",
                    "initial": "E.A.",
                    "last": "Emini"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Gruber"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Schmoele-Thoma"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.05.010",
            "firstpage": "3585",
            "issn": "0264410X",
            "lastpage": "3593",
            "pmid": "23688527",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine",
            "volume": "31"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Richard N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "Alejandra",
                    "initial": "A.",
                    "last": "Gurtman"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Frenck"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Strout"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Trammel"
                },
                {
                    "first": "Daniel A.",
                    "initial": "D.A.",
                    "last": "Scott"
                },
                {
                    "first": "Emilio A.",
                    "initial": "E.A.",
                    "last": "Emini"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Gruber"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Schmoele-Thoma"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.02.002",
            "firstpage": "2364",
            "issn": "0264410X",
            "lastpage": "2374",
            "pmid": "24606865",
            "pub_year": 2014,
            "title": "Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age",
            "volume": "32"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                }
            ],
            "doi": "10.1007/82-2010-31",
            "firstpage": "341",
            "issn": "0070217X",
            "lastpage": "357",
            "pmid": "20473790",
            "pub_year": 2010,
            "title": "VZV T cell-mediated immunity",
            "volume": "342"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Gilbert"
                },
                {
                    "first": "Erin E.",
                    "initial": "E.E.",
                    "last": "Gabriel"
                },
                {
                    "first": "Xiaopeng",
                    "initial": "X.",
                    "last": "Miao"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                }
            ],
            "doi": "10.1093/infdis/jiu279",
            "firstpage": "1573",
            "issn": "00221899",
            "lastpage": "1581",
            "pmid": "24823623",
            "pub_year": 2014,
            "title": "Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked Immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve",
            "volume": "210"
        }
    },
    "body_text": [
        {
            "endOffset": 36650,
            "parents": [],
            "secId": "s0080",
            "sentence": "Overall, the percentages of participants reporting solicited general symptoms appeared to be higher in the Co-Ad than in the Control group.",
            "startOffset": 36511,
            "title": "Discussion"
        },
        {
            "endOffset": 21344,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 21343,
                    "startOffset": 21336
                },
                "b0115": {
                    "endOffset": 21343,
                    "startOffset": 21336
                },
                "b0120": {
                    "endOffset": 21343,
                    "startOffset": 21336
                }
            },
            "secId": "s0005",
            "sentence": "It was also recommended for populations at high risk for pneumococcal disease, including elderly, in Australia, Japan and most European countries [22\u201324].",
            "startOffset": 21190,
            "title": "Introduction"
        },
        {
            "endOffset": 31830,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The median duration of solicited local symptoms was 4 days or less.",
            "startOffset": 31763,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35883,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 35882,
                    "startOffset": 35878
                }
            },
            "secId": "s0080",
            "sentence": "Similarly, another study found no interference in responses to either influenza antigens or to 4 representative pneumococcal polysaccharide antigens when an MF59-adjuvanted influenza vaccine was administered concomitantly with PPSV23 in adults \u226565 YOA [37].",
            "startOffset": 35626,
            "title": "Discussion"
        },
        {
            "endOffset": 32167,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Pain was the most frequent solicited local symptom in both groups, reported by 77.3% and 68.7% of participants after the first dose of RZV, by 71.6% and 69.9% of participants after the second dose of RZV and by 52.1 and 39.2% of participants at the injection site of PPSV23 in the Co-Ad and Control groups, respectively (Fig. 2A and C).",
            "startOffset": 31831,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24554,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Adults were excluded from participation if they had previously received any pneumococcal, VZV or HZ vaccine, had a history of HZ, were administered or planning to use any investigational or non-registered product or vaccine or non-study vaccine from 30 days prior to inclusion in the study through 30 days after the second dose of RZV, had a documented pneumococcal infection within 5 years, had received immunosuppressants or other immune-modifying drugs for more than 14 consecutive days within 6 months or had received long-acting immune-modifying drugs 6 months before first study vaccination.",
            "startOffset": 23957,
            "title": "Study participants"
        },
        {
            "endOffset": 37637,
            "parents": [],
            "secId": "s0080",
            "sentence": "This study was open label by design, which might introduce bias for safety related endpoints.",
            "startOffset": 37544,
            "title": "Discussion"
        },
        {
            "endOffset": 40623,
            "parents": [],
            "secId": "s0095",
            "sentence": "PR receives Investigator stipends from Medicor Research Inc.",
            "startOffset": 40563,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 26931,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.",
            "startOffset": 26789,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 26594,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "VRR for anti-gE was defined as the percentage of participants who had at least: (i) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for participants who were seropositive at baseline, or (ii) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies\u2019 cut-off value for seropositivity, for participants who were seronegative at baseline.",
            "startOffset": 26114,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 25460,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The 23 serotypes are: 1, 2, 3, 4, 5, 6B, 7F, 8, 9 N, 9 V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F.",
            "startOffset": 25340,
            "title": "Study vaccines"
        },
        {
            "endOffset": 40229,
            "parents": [],
            "secId": "s0095",
            "sentence": "LO owns GSK stock.",
            "startOffset": 40211,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 20563,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 20562,
                    "startOffset": 20558
                }
            },
            "secId": "s0005",
            "sentence": "High efficacy against the incidence of HZ (91.3%) and PHN (88.8%) was also observed in individuals \u226570 YOA [16].",
            "startOffset": 20451,
            "title": "Introduction"
        },
        {
            "endOffset": 22254,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase III, open-label, randomized and controlled multi-center study conducted at 9 study centers \u2013 US (3), Canada (3) and Estonia (3) \u2013 between March 2014 and June 2016.",
            "startOffset": 22074,
            "title": "Study design"
        },
        {
            "endOffset": 30843,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-second RZV dose, VRRs for anti-gE antibody concentrations were 98.3% in each study group and the VRR in the Co-Ad group met the first co-primary objective (LL of the 95% CI \u226560%) (Table 2).",
            "startOffset": 30639,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34962,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 34936,
                    "startOffset": 34923
                },
                "b0080": {
                    "endOffset": 34936,
                    "startOffset": 34923
                },
                "b0150": {
                    "endOffset": 34936,
                    "startOffset": 34923
                },
                "b0155": {
                    "endOffset": 34911,
                    "startOffset": 34904
                },
                "b0160": {
                    "endOffset": 34936,
                    "startOffset": 34923
                }
            },
            "secId": "s0080",
            "sentence": "The overall immunogenicity and safety profile of RZV observed herein are consistent with findings of previous studies on immunogenicity [30,31] and safety [15,16,30,32] of RZV in adults \u226550 YOA.",
            "startOffset": 34768,
            "title": "Discussion"
        },
        {
            "endOffset": 40659,
            "parents": [],
            "secId": "s0095",
            "sentence": "AP and JT have nothing to disclose.",
            "startOffset": 40624,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 30622,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The gender distribution was similar in both groups.",
            "startOffset": 30571,
            "title": "Study participants"
        },
        {
            "endOffset": 33412,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Overall, solicited AEs were reported by similar percentages of participants in the 2 study groups (Table 3).",
            "startOffset": 33304,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33812,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Two deaths and 1 pIMD occurred in each of the study groups.",
            "startOffset": 33753,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 19395,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 19394,
                    "startOffset": 19389
                },
                "b0025": {
                    "endOffset": 19394,
                    "startOffset": 19389
                }
            },
            "secId": "s0005",
            "sentence": "The most common complication of HZ is postherpetic neuralgia (PHN), chronic pain that can last for months or even years after the zoster rash has resolved [4,5].",
            "startOffset": 19234,
            "title": "Introduction"
        },
        {
            "endOffset": 25951,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "Humoral immune responses to the vaccines were assessed from blood samples collected from the Co-Ad group at D0 (pre-vaccination for both vaccines), M1 (1 month post-vaccination for PPSV23), and M3 (1 month post-second dose of RZV); and from samples collected from the Control group at D0 (pre-vaccination for PPSV23), M1 (1 month post-vaccination for PPSV23), M2 (pre-vaccination for RZV), and M5 (1 month post-second dose of RZV).",
            "startOffset": 25520,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 39769,
            "parents": [],
            "secId": "s0095",
            "sentence": "TCH and HL were employed by the GSK group of companies at the time this study was designed and initiated.",
            "startOffset": 39664,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 33146,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "After the second dose of RZV, which was always administered as a standalone vaccine, fatigue was the most frequent solicited general symptom, reported by 46.0% and 41.5% of participants in the Co-Ad and Control groups, respectively.",
            "startOffset": 32914,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39641,
            "parents": [],
            "secId": "s0090",
            "sentence": "Prevnar 13 and Prevenar 13 are trademarks of Pfizer Inc.",
            "startOffset": 39585,
            "title": "Trademarks"
        },
        {
            "endOffset": 23878,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Adults \u226550 YOA at the time of first vaccination were eligible for inclusion.",
            "startOffset": 23802,
            "title": "Study participants"
        },
        {
            "endOffset": 25142,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The RZV (Shingrix, GSK1437173A, GSK) contained 50 \u03bcg of VZV gE and the AS01B Adjuvant System containing 50 \u03bcg MPL (3-O-desacyl-4\u2032-monophosphoryl lipid A; produced by GSK), 50 \u03bcg QS-21 (Quillaja saponaria Molina, fraction 21; licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation) and liposome per 0.5 mL of reconstituted vaccine.",
            "startOffset": 24760,
            "title": "Study vaccines"
        },
        {
            "endOffset": 22869,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 22753,
            "title": "Study design"
        },
        {
            "endOffset": 22752,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol was reviewed and approved by Independent Ethics Committees.",
            "startOffset": 22674,
            "title": "Study design"
        },
        {
            "endOffset": 28639,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Descriptive analyses of safety and reactogenicity were based on the total vaccinated cohort (TVC) and included all participants with at least 1 documented administered vaccine dose.",
            "startOffset": 28458,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40210,
            "parents": [],
            "secId": "s0095",
            "sentence": "LO was employed by the GSK group of companies until end Feb 2018 and is employee of CureVacAG as of March 1st 2018.",
            "startOffset": 40095,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 19726,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 19725,
                    "startOffset": 19722
                }
            },
            "secId": "s0005",
            "sentence": "Immunocompromised individuals are also at higher risk of developing HZ, regardless of age [6].",
            "startOffset": 19632,
            "title": "Introduction"
        },
        {
            "endOffset": 36154,
            "parents": [],
            "secId": "s0080",
            "sentence": "Taken together, these findings suggest that immune responses to antigens from MF59- or AS01-adjuvanted vaccines are not affected by their co-administration with another vaccine, nor do these adjuvants affect the response to any antigens from the co-administered vaccine.",
            "startOffset": 35884,
            "title": "Discussion"
        },
        {
            "endOffset": 40562,
            "parents": [],
            "secId": "s0095",
            "sentence": "MF is employed as Investigator at the Colchester Research Group, which is owned by his wife, Dr Linda Ferguson.",
            "startOffset": 40451,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 27366,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Unsolicited AEs were recorded for 30 days (D0\u2013D29) after each vaccination.",
            "startOffset": 27292,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 20769,
            "parents": [],
            "secId": "s0005",
            "sentence": "Similar to HZ, the risk of pneumococcal pneumonia and invasive pneumococcal disease (IPD) is higher in adults \u226550 YOA.",
            "startOffset": 20651,
            "title": "Introduction"
        },
        {
            "endOffset": 39006,
            "parents": [],
            "secId": "s0080",
            "sentence": "A plain language graphical summary contextualizing the results and potential clinical research relevance and impact is displayed in the Focus on Patient Section (Fig. 3).",
            "startOffset": 38836,
            "title": "Discussion"
        },
        {
            "endOffset": 22389,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were randomized (1:1) using a central randomization system on internet (SBIR, GSK) to one of the two parallel study arms.",
            "startOffset": 22255,
            "title": "Study design"
        },
        {
            "endOffset": 19988,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 19987,
                    "startOffset": 19980
                },
                "b0060": {
                    "endOffset": 19987,
                    "startOffset": 19980
                }
            },
            "secId": "s0005",
            "sentence": "A live-attenuated VZV vaccine (Zostavax, ZVL) was found to reduce incidence of HZ by 69.8% and 51.3% in adults 50\u201359 and \u226560 YOA, respectively, and incidence of PHN by 66.5% in adults \u226560 YOA [11,12].",
            "startOffset": 19788,
            "title": "Introduction"
        },
        {
            "endOffset": 31434,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "GMTControl/GMTCo-Ad ratiosadjusted ranged from 0.89 to 1.15 for these 12 serotypes with the ULs of the corresponding 95% CIs <2, thus meeting the third co-primary objective and demonstrating the non-inferiority of the Co-ad group vs the Control group (Table 2).",
            "startOffset": 31173,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34768,
            "parents": [],
            "secId": "s0080",
            "sentence": "No safety concerns were raised.",
            "startOffset": 34737,
            "title": "Discussion"
        },
        {
            "endOffset": 26788,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 26730,
                    "startOffset": 26726
                },
                "b0145": {
                    "endOffset": 26787,
                    "startOffset": 26783
                }
            },
            "secId": "s0035",
            "sentence": "Opsonophagocytic activity for antibodies against each of the 12 selected pneumococcal serotypes was measured using a HL60 cell line [28] in a Multiplex Opsonophagocytic Assay (MOPA) format [29].",
            "startOffset": 26594,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 40094,
            "parents": [],
            "secId": "s0095",
            "sentence": "HL is currently employed by Pfizer Inc. and receives salary and stock as part of his compensation.",
            "startOffset": 39996,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 36511,
            "parents": [],
            "secId": "s0080",
            "sentence": "However, local symptoms at the PPSV23 injection site tended to be more frequent in the Co-Ad than in the Control group and local symptoms at the RZV injection site tended to be more frequent than at the PPSV23 injection site in both study groups.",
            "startOffset": 36265,
            "title": "Discussion"
        },
        {
            "endOffset": 38835,
            "parents": [],
            "secId": "s0080",
            "sentence": "As PCV13 is also approved in the US for prevention of pneumococcal infections in older adults, it may be worth to explore its co-administration with RZV in a future trial.",
            "startOffset": 38664,
            "title": "Discussion"
        },
        {
            "endOffset": 31078,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The GMCControl/GMCCo-Ad ratioadjusted at 1 month after the second dose of RZV was 1.02 (95% CI 0.93\u20131.11), meeting the second co-primary objective and demonstrating the non-inferiority of the Co-ad group vs the Control group (Table 2).",
            "startOffset": 30843,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35281,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 35280,
                    "startOffset": 35276
                }
            },
            "secId": "s0080",
            "sentence": "In contrast with the lack of immune interference between RZV and PPSV23 when co-administered, a randomized clinical study revealed a reduced immune response to ZVL measured by anti-VZV ELISA in adults \u226560 YOA who received ZVL and PPSV23 concomitantly compared to adults who received these 2 vaccines 4 weeks apart [33].",
            "startOffset": 34962,
            "title": "Discussion"
        },
        {
            "endOffset": 30368,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Of these, 829 (412 Co-Ad, 417 Control) were included in the ATP cohort for immunogenicity and 842 (423 Co-Ad, 419 Control) completed the study up to the last phone contact for safety (Fig. 1).",
            "startOffset": 30176,
            "title": "Study participants"
        },
        {
            "endOffset": 19233,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19232,
                    "startOffset": 19227
                },
                "b0010": {
                    "endOffset": 19232,
                    "startOffset": 19227
                },
                "b0015": {
                    "endOffset": 19232,
                    "startOffset": 19227
                }
            },
            "secId": "s0005",
            "sentence": "Reactivation of latent varicella-zoster virus (VZV) leads to herpes zoster (HZ) which typically manifests as a painful vesicular dermatomal rash [1\u20133].",
            "startOffset": 19082,
            "title": "Introduction"
        },
        {
            "endOffset": 27081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Diary cards were provided to participants at each vaccination visit to record solicited and unsolicited adverse events (AEs).",
            "startOffset": 26956,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 25339,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The PPSV23 (Pneumovax 23, Merck Sharp & Dohme Corp.) contained 25 \u00b5g of capsular polysaccharide from each of 23 pneumococcal serotypes and 0.25% phenol as preservative per 0.5 mL monodose syringe.",
            "startOffset": 25143,
            "title": "Study vaccines"
        },
        {
            "endOffset": 37134,
            "parents": [],
            "secId": "s0080",
            "sentence": "The study was however not designed to assess differences in reactogenicity and all safety results were descriptive.",
            "startOffset": 37019,
            "title": "Discussion"
        },
        {
            "endOffset": 23490,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Co-primary objectives of the study were to evaluate the vaccine response rate (VRR) to RZV 1 month post-second dose of the vaccine in the Co-Ad group; to demonstrate the non-inferiority of the anti-gE geometric mean concentrations (GMCs) following the second RZV dose in the Co-Ad vs Control group; and to demonstrate the non-inferiority of PPSV23 immunogenicity in the Co-Ad vs Control group for 12 selected serotypes included in PPSV23 (1, 3, 4, 5, 6B, 7F, 9 V, 14, 18C, 19A, 19F and 23F), by comparing opsonophagocytic activity geometric mean titers (GMTs).",
            "startOffset": 22930,
            "title": "Study design"
        },
        {
            "endOffset": 20952,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 20951,
                    "startOffset": 20947
                }
            },
            "secId": "s0005",
            "sentence": "The 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23, PPSV23) is approved for use in adults \u226550 YOA, including populations at increased risk for pneumococcal disease [19].",
            "startOffset": 20770,
            "title": "Introduction"
        },
        {
            "endOffset": 32552,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The median duration of solicited general symptoms was less than or equal to 2 days.",
            "startOffset": 32469,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 30444,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Demographic characteristics were comparable between study groups (Table 1).",
            "startOffset": 30369,
            "title": "Study participants"
        },
        {
            "endOffset": 38390,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 38316,
                    "startOffset": 38312
                }
            },
            "secId": "s0080",
            "sentence": "Although VZV-specific cell-mediated immunity is believed to be the main mechanistic driver of protection against HZ [40], antibody levels may reflect such cellular immune responses just as well.",
            "startOffset": 38196,
            "title": "Discussion"
        },
        {
            "endOffset": 37812,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 37811,
                    "startOffset": 37804
                },
                "b0195": {
                    "endOffset": 37811,
                    "startOffset": 37804
                }
            },
            "secId": "s0080",
            "sentence": "Previous studies revealed hyporesponsiveness to PCV13 when administered 1 year after PPSV23 [38,39].",
            "startOffset": 37712,
            "title": "Discussion"
        },
        {
            "endOffset": 21773,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 21772,
                    "startOffset": 21768
                }
            },
            "secId": "s0005",
            "sentence": "In 2015, less than one third of the elderly population in the US was vaccinated against HZ and less than two thirds against pneumococcal infection [27].",
            "startOffset": 21621,
            "title": "Introduction"
        },
        {
            "endOffset": 29308,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The first co-primary objective was met if the lower limit (LL) of the 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group was at least 60%.",
            "startOffset": 29148,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 38195,
            "parents": [],
            "secId": "s0080",
            "sentence": "Our study evaluated humoral rather than cell-mediated immune responses.",
            "startOffset": 38124,
            "title": "Discussion"
        },
        {
            "endOffset": 22038,
            "parents": [],
            "secId": "s0005",
            "sentence": "As co-administration may help overcoming programmatic barriers of vaccination in adults \u226550 YOA, this study evaluated the immunogenicity and safety of both vaccines when the first dose of RZV was co-administered with PPSV23 compared to a sequential administration.",
            "startOffset": 21774,
            "title": "Introduction"
        },
        {
            "endOffset": 28376,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "A suspected case of HZ was defined as a new rash characteristic of HZ and clinically diagnosed as such by the investigator.",
            "startOffset": 28253,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 22930,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered on ClinicalTrials.gov (NCT02045836).",
            "startOffset": 22870,
            "title": "Study design"
        },
        {
            "endOffset": 32468,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Solicited general symptoms were reported by 64.4% (12.2% for grade 3) of participants when the first dose of RZV and PPSV23 were co-administered, 48.0% (5.7% for grade 3) of participants after receiving first RZV dose alone and by 37.0% (2.1% for grade 3) of participants after receiving PPSV23 alone.",
            "startOffset": 32167,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 29769,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "Non-inferiority of anti-pneumococcal antibody MOPA GMTs 1 month post-PPSV23 vaccination was demonstrated if the UL of the 2-sided 95% CI of the GMTControl/GMTCo-Ad ratioadjusted was below 2 for each of the 12 selected serotypes.",
            "startOffset": 29541,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 37269,
            "parents": [],
            "secId": "s0080",
            "sentence": "The incidence of SAEs and pIMDs was balanced between groups and none were considered by investigators causally related to vaccination.",
            "startOffset": 37135,
            "title": "Discussion"
        },
        {
            "endOffset": 38037,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 38036,
                    "startOffset": 38032
                }
            },
            "secId": "s0080",
            "sentence": "Although in our study, the control group received RZV at 2 and 4 months after PPSV23, the humoral immune responses to RZV were in similar ranges as those observed in two large pivotal phase III efficacy trials with RZV [31].",
            "startOffset": 37813,
            "title": "Discussion"
        },
        {
            "endOffset": 19537,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 19536,
                    "startOffset": 19531
                },
                "b0035": {
                    "endOffset": 19536,
                    "startOffset": 19531
                },
                "b0040": {
                    "endOffset": 19536,
                    "startOffset": 19531
                },
                "b0045": {
                    "endOffset": 19536,
                    "startOffset": 19531
                }
            },
            "secId": "s0005",
            "sentence": "The risk and incidence of HZ increases significantly with age likely due to an age-dependent decline in VZV-specific cellular immunity [6\u20139].",
            "startOffset": 19396,
            "title": "Introduction"
        },
        {
            "endOffset": 33753,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Unsolicited symptoms considered related to vaccination by the investigator were reported by 34 (7.9%) participants in the Co-Ad and 28 (6.5%) participants in the Control group.",
            "startOffset": 33577,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33912,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The reported pIMDs were sarcoidosis in the Co-Ad group and ulcerative colitis in the Control group.",
            "startOffset": 33813,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27896,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Unsolicited AEs were graded on a scale from 1 (mild) to 3 (severe: prevented normal activity).",
            "startOffset": 27802,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 40450,
            "parents": [],
            "secId": "s0095",
            "sentence": "CM receives salary from Business&Decision LS for full time insourcement at the GSK group of companies.",
            "startOffset": 40348,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 28050,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were recorded from enrollment through 12 months after second dose of RZV for each group.",
            "startOffset": 27896,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 39252,
            "parents": [],
            "secId": "s0085",
            "sentence": "Humoral immune responses induced by each vaccine were similar to those induced by their separate administration.",
            "startOffset": 39140,
            "title": "Conclusions"
        },
        {
            "endOffset": 20124,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 20123,
                    "startOffset": 20119
                }
            },
            "secId": "s0005",
            "sentence": "Currently, in the United States (US), ZVL is approved for use in immunocompetent adults \u226550 YOA and recommended for those \u226560 YOA [13].",
            "startOffset": 19989,
            "title": "Introduction"
        },
        {
            "endOffset": 27291,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Solicited local (injection site pain, redness and swelling) and general (fatigue, fever, gastrointestinal symptoms, headache, myalgia and shivering) AEs were recorded for 7 days (D0\u2013D6) after each vaccination.",
            "startOffset": 27082,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 29122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Unadjusted and adjusted GMCs and GMTs, as well as associated 2-sided 95% confidence intervals (CIs) were obtained descriptively and by use of Analysis of Covariance (ANCOVA) model, respectively.",
            "startOffset": 28928,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37018,
            "parents": [],
            "secId": "s0080",
            "sentence": "These findings suggest that reactogenicity profile of RZV is not amplified by the co-administration with PPSV23.",
            "startOffset": 36906,
            "title": "Discussion"
        },
        {
            "endOffset": 32726,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Myalgia was the most frequent solicited general symptom in the Co-Ad group, reported by 43.8% of participants after receiving the first dose of RZV and PPSV23 concomitantly.",
            "startOffset": 32553,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39529,
            "parents": [],
            "secId": "s0090",
            "sentence": "Pneumovax and Zostavax are trademarks of Merck Sharpe & Dohme corp.",
            "startOffset": 39462,
            "title": "Trademarks"
        },
        {
            "endOffset": 20450,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 20449,
                    "startOffset": 20445
                }
            },
            "secId": "s0005",
            "sentence": "RZV showed 97.2% overall efficacy for the prevention of HZ in adults aged \u226550 YOA [15].",
            "startOffset": 20363,
            "title": "Introduction"
        },
        {
            "endOffset": 32913,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "By comparison, myalgia was reported in the Control group by 29.5% of participants after the first dose of RZV and by 20.2% after PPSV23, when receiving the vaccines separately (Fig. 2B).",
            "startOffset": 32727,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 30175,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "A total of 865 adults (TVC: 432 Co-Ad, 433 Control) were enrolled, randomized and received at least one study vaccine dose.",
            "startOffset": 30052,
            "title": "Study participants"
        },
        {
            "endOffset": 40347,
            "parents": [],
            "secId": "s0095",
            "sentence": "LO owns stock options as part of her employee remuneration.",
            "startOffset": 40288,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 33998,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Neither pIMDs nor fatalities were considered related to vaccination by investigators.",
            "startOffset": 33913,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35625,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 35624,
                    "startOffset": 35620
                }
            },
            "secId": "s0080",
            "sentence": "In line with our findings, no immunological interference was observed for either vaccine when the first dose of RZV was co-administered with a seasonal Quadrivalent inactivated influenza Vaccine in adults \u226550 YOA [36].",
            "startOffset": 35407,
            "title": "Discussion"
        },
        {
            "endOffset": 30570,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The mean age was 63.2 (\u00b18.4) years, and the majority of participants were of Caucasian ancestry (\u226593.8%) in each study group.",
            "startOffset": 30445,
            "title": "Study participants"
        },
        {
            "endOffset": 37712,
            "parents": [],
            "secId": "s0080",
            "sentence": "Immunogenicity was assessed from samples handled by blinded lab personnel.",
            "startOffset": 37638,
            "title": "Discussion"
        },
        {
            "endOffset": 20651,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 20650,
                    "startOffset": 20643
                },
                "b0090": {
                    "endOffset": 20650,
                    "startOffset": 20643
                }
            },
            "secId": "s0005",
            "sentence": "RZV is approved for use in immunocompetent adults \u226550 YOA in Canada and the US [17,18].",
            "startOffset": 20564,
            "title": "Introduction"
        },
        {
            "endOffset": 29889,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "Safety of the study vaccines was assessed as a secondary objective using descriptive statistics.",
            "startOffset": 29793,
            "title": "Secondary objective"
        },
        {
            "endOffset": 35407,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 35406,
                    "startOffset": 35399
                },
                "b0175": {
                    "endOffset": 35406,
                    "startOffset": 35399
                }
            },
            "secId": "s0080",
            "sentence": "However, concomitant administration of these vaccines did not seem to negatively impact protection by ZVL against HZ [34,35].",
            "startOffset": 35282,
            "title": "Discussion"
        },
        {
            "endOffset": 23781,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The evaluation of the safety and reactogenicity of RZV and PPSV23 when co-administered or administered sequentially was a secondary objective.",
            "startOffset": 23639,
            "title": "Study design"
        },
        {
            "endOffset": 31172,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Anti-pneumococcal OPA GMTs for the 12 selected serotypes were similar in the two study groups.",
            "startOffset": 31078,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33576,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Within 30 days after vaccination, unsolicited AEs were reported by 132 (30.6%) and 140 (32.3%) participants in the Co-Ad and Control groups, respectively (Table 3).",
            "startOffset": 33412,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24743,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Adults with cerebrospinal fluid leaks, cochlear implants, chronic renal failure, nephrotic syndrome and functional or anatomic asplenia, were also excluded from participation in the study.",
            "startOffset": 24555,
            "title": "Study participants"
        },
        {
            "endOffset": 38664,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 38663,
                    "startOffset": 38659
                }
            },
            "secId": "s0080",
            "sentence": "Additionally, humoral immune responses to ZVL were shown to strongly correlate with protection against HZ [41].",
            "startOffset": 38553,
            "title": "Discussion"
        },
        {
            "endOffset": 31762,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Solicited local symptoms were reported by 84.1% (12.6% for grade 3) of participants when the first dose of RZV and PPSV23 were co-administered, 73.0% (7.6% for grade 3) of participants after receiving first RZV dose alone, and by 41.3% (1.6% for grade 3) of participants after receiving PPSV23 alone.",
            "startOffset": 31462,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21621,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 21520,
                    "startOffset": 21516
                },
                "b0130": {
                    "endOffset": 21620,
                    "startOffset": 21616
                }
            },
            "secId": "s0005",
            "sentence": "In the US, the 13-valent pneumococcal conjugate vaccine (Prevnar 13/Prevenar 13, PCV13) has been recommended in addition to PPSV23 for adults \u226565 YOA as of September 2014 [25] and for all persons aged \u226519 YOA at increased risk for pneumococcal disease as of October 2012 [26].",
            "startOffset": 21345,
            "title": "Introduction"
        },
        {
            "endOffset": 34274,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "One suspected HZ case occurred in the Co-Ad group 302 days after administration of second RZV dose.",
            "startOffset": 34175,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34736,
            "parents": [],
            "secId": "s0080",
            "sentence": "All co-primary immunogenicity objectives of the study were met: VRR to RZV in the Co-Ad group and non-inferiority of immune responses to RZV and to PPSV23 when co-administered as compared to their sequential administration.",
            "startOffset": 34513,
            "title": "Discussion"
        },
        {
            "endOffset": 19787,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 19786,
                    "startOffset": 19783
                }
            },
            "secId": "s0005",
            "sentence": "Vaccination is known to reduce the risk of developing HZ [7].",
            "startOffset": 19726,
            "title": "Introduction"
        },
        {
            "endOffset": 23956,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Written informed consent was provided by all participants before study start.",
            "startOffset": 23879,
            "title": "Study participants"
        },
        {
            "endOffset": 28252,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "An SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolonged existing hospitalization, resulted in disability or incapacity.",
            "startOffset": 28051,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 39846,
            "parents": [],
            "secId": "s0095",
            "sentence": "TCH and HL received salary and stock as part of their employee remuneration.",
            "startOffset": 39770,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 22674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants in the Co-Ad group received the first dose of RZV and PPSV23, co-administered at Day 0 (D0), in different arms and the second dose of RZV at Month 2 (M2), while participants in the Control group received PPSV23 at D0, first dose of RZV at M2 and second dose of RZV at M4.",
            "startOffset": 22390,
            "title": "Study design"
        },
        {
            "endOffset": 38123,
            "parents": [],
            "secId": "s0080",
            "sentence": "No generally accepted immunologic correlate of protection has been established for HZ.",
            "startOffset": 38037,
            "title": "Discussion"
        },
        {
            "endOffset": 29541,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "Non-inferiority of the Co-Ad vs the Control group in terms of anti-gE GMCs was demonstrated if the upper limit (UL) of the 2-sided 95% CI of the post-vaccination GMCControl/GMCCo-Ad ratioadjusted was below a pre-defined limit of 1.5.",
            "startOffset": 29308,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 36905,
            "parents": [],
            "secId": "s0080",
            "sentence": "This apparent difference is induced by the higher percentage of participants reporting solicited general symptoms after the first RZV dose in the Co-Ad group, likely attributable to the additional systemic reactions related to the co-administered PPSV23.",
            "startOffset": 36651,
            "title": "Discussion"
        },
        {
            "endOffset": 39139,
            "parents": [],
            "secId": "s0085",
            "sentence": "Co-administration of RZV with PPSV23 was well tolerated and no safety concerns were raised in either of the study groups.",
            "startOffset": 39018,
            "title": "Conclusions"
        },
        {
            "endOffset": 28927,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The analysis of immunogenicity was based on the according-to-protocol (ATP) cohort for immunogenicity and included participants who met all eligibility criteria, complied with the study procedures and intervals allowed for the analysis and for whom immunogenicity results were available.",
            "startOffset": 28640,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 20362,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 20361,
                    "startOffset": 20357
                }
            },
            "secId": "s0005",
            "sentence": "A recombinant vaccine, containing the VZV glycoprotein E (gE) and the AS01B Adjuvant System (Shingrix, RZV), elicits strong anti-gE cellular and humoral immune responses that persist above pre-vaccination levels for at least 9 years [14].",
            "startOffset": 20124,
            "title": "Introduction"
        },
        {
            "endOffset": 27801,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "All solicited AEs were graded on a scale from 0 (absent or characterized by a surface diameter <20 mm for swelling and redness, oral temperature <37.5 \u00b0C for fever) to 3 (characterized by a surface diameter >100 mm [for redness and swelling], a tympanic/oral/axillary temperature >39 \u00b0C [for fever], significant at rest and preventing normal every day activities [for pain] or prevented normal activity [for all other solicited AEs]).",
            "startOffset": 27367,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 33303,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Proportions of participants reporting at least 1 general or local solicited reaction after the second RZV dose were similar in the 2 study groups (Fig. 2C).",
            "startOffset": 33147,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37543,
            "parents": [],
            "secId": "s0080",
            "sentence": "The strengths of the study were its overall power (\u223c90%), the age (\u226550 YOA) and geographic diversity of the participants, the high compliance with study procedures and the high number of participants completing the study, while racial homogeneity was one of its limitations.",
            "startOffset": 37269,
            "title": "Discussion"
        },
        {
            "endOffset": 39452,
            "parents": [],
            "secId": "s0085",
            "sentence": "These results support the concomitant administration of RZV and PPSV23 at the same clinic visit, which might increase opportunities of older adults for vaccination against HZ and pneumococcal disease.",
            "startOffset": 39252,
            "title": "Conclusions"
        },
        {
            "endOffset": 30023,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "A more detailed description of the statistical methods, including sample size calculation, is presented in the Supplementary material.",
            "startOffset": 29889,
            "title": "Secondary objective"
        },
        {
            "endOffset": 40287,
            "parents": [],
            "secId": "s0095",
            "sentence": "CH, IE and DW are employed by the GSK group of companies.",
            "startOffset": 40230,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 19631,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 19630,
                    "startOffset": 19626
                }
            },
            "secId": "s0005",
            "sentence": "The risk is highest in adults \u226550 years of age (YOA), in whom 60% of all HZ cases occur [10].",
            "startOffset": 19538,
            "title": "Introduction"
        },
        {
            "endOffset": 21189,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 21188,
                    "startOffset": 21181
                },
                "b0105": {
                    "endOffset": 21188,
                    "startOffset": 21181
                }
            },
            "secId": "s0005",
            "sentence": "At the time this study was designed, PPSV23 was recommended by the US Centers for Disease Control and Prevention (CDC) for the prevention of IPD in adults \u226565 YOA and in adults \u226519 YOA at increased risk for pneumococcal disease [20,21].",
            "startOffset": 20953,
            "title": "Introduction"
        },
        {
            "endOffset": 34512,
            "parents": [],
            "secId": "s0080",
            "sentence": "This study showed that immunogenicity of two doses of RZV was unaffected by the co-administration of the first dose with PPSV23, and that immunogenicity of PPSV23 was also preserved when co-administered with the first RZV dose.",
            "startOffset": 34285,
            "title": "Discussion"
        },
        {
            "endOffset": 38552,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 38551,
                    "startOffset": 38547
                }
            },
            "secId": "s0080",
            "sentence": "Exploratory analyses showed a moderate positive correlation between humoral and cellular immune responses during the first 3 years following 2 doses of RZV [31].",
            "startOffset": 38391,
            "title": "Discussion"
        },
        {
            "endOffset": 36264,
            "parents": [],
            "secId": "s0080",
            "sentence": "The percentage of participants reporting local symptoms at the RZV injection site was similar in the 2 groups.",
            "startOffset": 36154,
            "title": "Discussion"
        },
        {
            "endOffset": 39584,
            "parents": [],
            "secId": "s0090",
            "sentence": "Shingrix is a trademark of the GSK group of companies.",
            "startOffset": 39530,
            "title": "Trademarks"
        },
        {
            "endOffset": 23638,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Of note, these 12 serotypes are common to currently approved pneumococcal vaccines PPSV23 and PCV13 in the countries where the study was conducted.",
            "startOffset": 23491,
            "title": "Study design"
        },
        {
            "endOffset": 26113,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "Anti-gE antibody concentrations were measured using an anti-gE enzyme-linked immunosorbent assay (ELISA) with a cut-off of 97 milli International Units (mIU)/mL.",
            "startOffset": 25952,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 34175,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Non-fatal SAEs were reported by 15 and 17 participants in the Co-Ad and Control groups, respectively, none of which were considered related to vaccination by the investigators.",
            "startOffset": 33999,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28435,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "HZ and/or HZ complications were collected until study end.",
            "startOffset": 28377,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 39995,
            "parents": [],
            "secId": "s0095",
            "sentence": "TCH is co-inventor of the patent application related to the vaccine used in this study and is currently a consultant for the GSK group of companies.",
            "startOffset": 39847,
            "title": "Declaration of interest"
        }
    ],
    "docId": "S0264410X18307874",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "celine.x.marechal@gsk.com",
                "first": "C\u00e9line",
                "initial": "C.",
                "last": "Mar\u00e9chal"
            },
            {
                "email": "himallal@pfizer.com",
                "first": "Himal",
                "initial": "H.",
                "last": "Lal"
            },
            {
                "email": "airi@std.ee",
                "first": "Airi",
                "initial": "A.",
                "last": "Poder"
            },
            {
                "email": "MFtruroclinics@eastlink.ca",
                "first": "Murdo",
                "initial": "M.",
                "last": "Ferguson"
            },
            {
                "email": "igwebuike.x.enweonye@gsk.com",
                "first": "Igwebuike",
                "initial": "I.",
                "last": "Enweonye"
            },
            {
                "email": "thomas.heineman@genocea.com",
                "first": "Thomas C.",
                "initial": "T.C.",
                "last": "Heineman"
            },
            {
                "email": "caroline.c.herve@gsk.com",
                "first": "Caroline",
                "initial": "C.",
                "last": "Herv\u00e9"
            },
            {
                "email": "paul_rheault@sympatico.ca",
                "first": "Paul",
                "initial": "P.",
                "last": "Rheault"
            },
            {
                "email": "jaak.talli@innomedica.ee",
                "first": "Jaak",
                "initial": "J.",
                "last": "Talli"
            },
            {
                "email": "dominique.wauters@gsk.com",
                "first": "Dominique",
                "initial": "D.",
                "last": "Wauters"
            },
            {
                "email": "cornelia.oostvogels@orange.fr",
                "first": "Lidia",
                "initial": "L.",
                "last": "Oostvogels"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.05.110",
        "firstpage": "4278",
        "issn": "0264410X",
        "keywords": [
            "23-Valent pneumococcal polysaccharide vaccine",
            "Adjuvanted recombinant zoster vaccine",
            "Herpes zoster",
            "Immune response",
            "Safety"
        ],
        "lastpage": "4286",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550\u202fyears of age: A randomized trial"
    }
}